Protagonist Therapeutics (PTGX) has moved from facing binary clinical risks to focusing on execution risks, supported by major pharmaceutical partners for commercialization without heavy infrastructure costs. The FDA approval of ICOTYDE and Priority Review status for rusfertide position PTGX to earn milestone payments and high-margin royalties through a capital-light revenue model. With over $620 million in cash and funding secured through 2028, PTGX reduces financing risks and aims for episodic profitability. Despite a premium valuation, the company offers a promising investment opportunity for those comfortable with regulatory and launch risks, backed by a validated peptide platform.
Herzfeld Credit Income Fund, Inc. announced its estimated net asset value (NAV) as of May 31, 2026, at $19.70 per share. The Fund focuses on credit-related investments, including CLO equity and junior debt tranches, aiming to maximize risk-adjusted r...
The Ontario Health Coalition has called on the Health Minister to halt Quest/LifeLabs from transferring Ontario patients' lab tests to U.S. reference labs following Quest's acquisition of LifeLabs in 2024. The coalition highlights risks including pat...
SpaceX's debut on Nasdaq saw over 522 million shares traded in one day, surpassing the combined trading volume of Apple, Microsoft, Tesla, Meta, and Google. The IPO raised $75 billion at $135 per share, marking the largest IPO ever and pushing SpaceX...
Monteverde & Associates PC, a top class action law firm, is investigating the mergers of Citizens National Corporation (CZNL), National Storage Affiliates Trust (NSA), CNB Bank Shares (CNBN), and Esquire Financial Holdings (ESQ). Shareholders of thes...
Boeing stock rose sharply by 5.4% following a nearly 5% drop in oil prices after the U.S. and Iran reached a peace agreement to reopen the Strait of Hormuz, a key route for global crude shipments. The reopening reduces jet-fuel costs, benefiting airl...
